A Phase 1, Open-label Study of BS006, an Oncolytic Virus, Administered by Intratumoral Injection in Patients With Advanced/Metastatic Solid Tumors
Latest Information Update: 30 Dec 2024
At a glance
- Drugs BS-006 (Primary)
- Indications Advanced breast cancer; Carcinoma; Male breast cancer; Malignant melanoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Binhui Biopharmaceutical
Most Recent Events
- 20 Dec 2023 Status changed from not yet recruiting to recruiting.
- 12 Jul 2023 New trial record